BioCentury
ARTICLE | Emerging Company Profile

FoRx: A broader look at DNA damage repair

FoRx is using synthetic lethality to attack a broad set of cancers with new DNA damage repair targets

April 24, 2020 9:14 PM UTC

University of Geneva spinout FoRx debuted this week with €10 million in seed funding, a trio of strategic investors, and a new approach to synthetic lethality that could expand the cancer-killing mechanism to a broad range of tumors.

The seed round announced on Wednesday was led by M Ventures, Novartis Venture Fund and Omega Funds. Pfizer Ventures and Life Science Partners also participated...